A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)-Reference-Cited by-同舟云学术

A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

Published:2022-05-30 Issue:4 Volume:116 Page:612-621
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Nakayama Hideki^ORCID,Ogawa Chitose,Sekimizu Masahiro,Fujisaki Hiroyuki,Kosaka Yoshiyuki,Hashimoto Hiroya,Saito Akiko M.,Horibe Keizo

Funder

Pfizer Japan

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-022-03388-8.pdf

Reference34 articles.

1. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–39.

2. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28:2339–47.

3. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a children’s oncology group study [corrected]. J Clin Oncol. 2008;26:3971–8.

4. Boue DR, LeBien TW. Expression and structure of CD22 in acute leukemia. Blood. 1988;71:1480–6.

5. Advani A, Coiffier B, Cruczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of b-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–93.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia;Haematologica;2024-05-10

2. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan;International Journal of Clinical Oncology;2024-04-30

3. Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1);International Journal of Hematology;2023-03-21

4. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas;Cancers;2022-10-14